Reproductive Pharmacology Flashcards
Leuprolide
Mech: GnRH analog with agonist properties when used in pulsatile fashion; antagonist properties when used in continuous fashion (down regulates GnRH receptor in pituitary –> decreased FSH/LH)
Clinical use: Infertility (pulsatile), prostate cancer (continuous, use with flutamide), uterine fibroids (continuous), precocious puberty (continuous)
Toxicity: Antiandrogen, nausea, vomiting
Testosterone, methyltestosterone
Mech: Agonist at androgen receptors
Clinical use: Treats hypogonadism and promotes development of secondary sex characteristics; stimulation of anabolism to promote recovery after burn or injury
Toxicity: causes masculinization in females; reduces intratesticular testosterone in males by inhibiting release of LH (via negative feedback), leading to gonadal atrophy. Premature closure of epiphyseal plates. Increases LDH, Decreases HDL
Finasteride
A 5-alpha reductase inhibitor (decreased conversion of testosterone to DHT). Useful in BPH. Also promotes hair growth–used to treat male pattern baldness
Flutamide
A nonsteroidal competitive inhibitor of androgens at the testosterone receptor. Used in prostate carcinoma
Ketoconazole
Inhibits steroid synthesis (inhibits 17,20-desmolase)
Used to treat PCOS to prevent hirsutism
Toxicity: gynecomastia, amenorrhea
Spironolactone
Inhibits steroid binding
Used to treat PCOS to prevent hirsutism
Toxicity: gynecomastia, amenorrhea
Estrogens (ethinyl estradiol, DES, mestranol)
Mech: bind estrogen receptors
Clinical use: Hypogonadism or ovarian failure, menstrual abnormalities, HRT in posmenopausal some; use in men with androgen-dependent prostate cancer
Toxicity: increased risk of endometrial cancer, bleeding in postmenopausal women, clear cell adenocarcinoma of vagina in females exposed to DES in utero, increased risk of thrombi. Contraindications: ER positive breast cancer, history of DVTs
Clomiphene
SERMs (selective estrogen receptor modulators)
Partial agonist at estrogen receptors in hypothalamus. Prevents normal feedback inhibition and increased release of LH and FSH from pituitary, which stimulates ovulation. Used to treat infertility and PCOS. May cause hot flashes, ovarian enlargement, multiple simultaneous pregnancies, and visual disturbances
Tamoxifen
SERM
Antagonist on breast tissue; used to treat and prevent recurrence of ER-positive breast cancer
Raloxifene
Agonist on bone; reduces resorption of bone; used to treat osteoporosis
Hormone replacement therapy
Used for relief or prevention of menopausal symptoms (e.g. hot flashes, vaginal atrophy) and osteoporosis (increased estrogen, decreased osteoclast activity)
Unopposed estrogen replacement therapy (ERT): increased risk of endometrial cancer, so progesterone is added. Possible increased CV risk
Anastrozole/exemestane
aromatase inhibitors used in postmenopausal women with breast cancer
Progestins
Mechanism: Bind progesterone receptors, reduce growth and increased vascularization of endometrium
Clinical use: used in oral contraceptives and in the treatment of endometrial cancer and abnormal uterine bleeding
Mifepristone (RU-486)
Mech: competitive inhibitor of progestins at progesterone receptors
Clinical use: termination of pregnancy. Administered with misoprostol (PGE1)
Toxicity: heavy bleeding, GI effects (nausea, vomiting, anorexia), abdominal pain
Oral contraception (synthetic progestins, estrogen)
Estrogen and progestins inhibit LH/FSH and thus prevent estrogen surge. No estrogen surge –> no LH surge –> no ovulation
Progestins cause thickening of the cervical mucus, thereby limiting access of sperm to uterus. Progestins also inhibit endometrial proliferation, thus making endometrium less suitable for the implantation of an embryo
Contraindications: smokers >35 years of age (increased risk of CV events), pts with history of thromboembolism and stroke or history of estrogen-dependent tumor